THER-09. IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES

BACKGROUND: Immunotherapy is increasingly used in patients with non-small cell lung cancer brain metastases (NSCLCBM). KRAS mutations are associated with worse prognosis and there is no FDA approved targeted therapy. KRAS mutations are associated with increased expression of PD-L1. We evaluated the...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neurooncol Adv
Prif Awduron: Lauko, Adam, Ali, Assad, Sagar, Soumya, Barnett, Addison, Li, Hong, Chao, Samuel, Pennell, Nathan, Stevens, Glen, Peereboom, David, Yu, Jennifer, Murphy, Erin, Angelov, Lilyana, Mohammadi, Alireza, Suh, John, Barnett, Gene, Ahluwalia, Manmeet
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2019
Pynciau:
Abstracts
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213262/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz014.052
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg